Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

BACKGROUND: Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients. MAIN BODY: A total number of 539 patients were enrolled in f...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabiee Rad, Mehrdad, Ghasempour Dabaghi, Ghazal, Habibi, Danial
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837360/
https://www.ncbi.nlm.nih.gov/pubmed/36633717
http://dx.doi.org/10.1186/s43044-023-00328-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837360/
https://www.ncbi.nlm.nih.gov/pubmed/36633717
http://dx.doi.org/10.1186/s43044-023-00328-7

Ejemplares similares